References
- Alpern, J. D., Lopez-Velez, R., & Stauffer, W. M. (2017). Access to benznidazole for Chagas disease in the United States-Cautious optimism? PLoS Neglected Tropical Diseases, 11(9), e0005794. doi:10.1371/journal.pntd.0005794
- Brak, K., Kerr, I. D., Barrett, K. T., Fuchi, N., Debnath, M., Ang, K., … Ellman, J. A. (2010). Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. Journal of Medicinal Chemistry, 53(4), 1763–1773. doi:10.1021/jm901633v
- da Silva-Junior, E. F., Barcellos Franca, P. H., Ribeiro, F. F., Bezerra Mendonca-Junior, F. J., Scotti, L., Scotti, M. T., … de Araujo-Junior, J. X. (2018). Molecular docking studies applied to a dataset of Cruzain inhibitors. Current Computer-Aided Drug Design, 14(1), 68–78. doi:10.2174/1573409913666170519112758
- Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 42717. doi:10.1038/srep42717
- Dumonteil, E., Herrera, C., & Buekens, P. (2019). A therapeutic preconceptional vaccine against Chagas disease: A novel indication that could reduce congenital transmission and accelerate vaccine development. PLoS Neglected Tropical Diseases, 13(1), e0006985. doi:10.1371/journal.pntd.0006985
- Forsyth, C. J., Hernandez, S., Olmedo, W., Abuhamidah, A., Traina, M. I., Sanchez, D. R., … Meymandi, S. K. (2016). Safety profile of nifurtimox for treatment of Chagas disease in the United States. Clinical Infectious Diseases, 63(8), 1056–1062. doi:10.1093/cid/ciw477
- Hernandez Alvarez, L., Barreto Gomes, D. E., Hernandez Gonzalez, J. E., & Pascutti, P. G. (2019). Dissecting a novel allosteric mechanism of cruzain: A computer-aided approach. PLoS One, 14(1), e0211227. doi:10.1371/journal.pone.0211227
- Herrera-Mayorga, V., Lara-Ramirez, E. E., Chacon-Vargas, K. F., Aguirre-Alvarado, C., Rodriguez-Paez, L., Alcantara-Farfan, V., … Rivera, G. (2019). Structure-based virtual screening and in vitro evaluation of new trypanosoma cruzi cruzain inhibitors. International Journal of Molecular Sciences, 20(7). doi:10.3390/ijms20071742
- Ndao, M., Beaulieu, C., Black, W. C., Isabel, E., Vasquez-Camargo, F., Nath-Chowdhury, M., … Nicoll-Griffith, D. A. (2014). Reversible cysteine protease inhibitors show promise for a Chagas disease cure. Antimicrobial Agents and Chemotherapy, 58(2), 1167–1178. doi:10.1128/AAC.01855-13
- Rogers, K. E., Keranen, H., Durrant, J. D., Ratnam, J., Doak, A., Arkin, M. R., & McCammon, J. A. (2012). Novel cruzain inhibitors for the treatment of Chagas' disease. Chemical Biology & Drug Design, 80(3), 398–405. doi:10.1111/j.1747-0285.2012.01416.x
- Santos, L. H., Waldner, B. J., Fuchs, J. E., Pereira, G. A. N., Liedl, K. R., Caffarena, E. R., & Ferreira, R. S. (2019). Understanding structure–activity relationships for trypanosomal cysteine protease inhibitors by simulations and free energy calculations. Journal of Chemical Information and Modeling, 59(1), 137–148. doi:10.1021/acs.jcim.8b00557
- WHO. (2019). Chagas disease (American trypanosomiasis). Retrieved from https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)
- Wiggers, H. J., Rocha, J. R., Cheleski, J., & Montanari, C. A. (2011). Integration of ligand- and target-based virtual screening for the discovery of cruzain inhibitors. Molecular Informatics, 30(6–7), 565–578. doi:10.1002/minf.201000146
- Wiggers, H. J., Rocha, J. R., Fernandes, W. B., Sesti-Costa, R., Carneiro, Z. A., Cheleski, J., … Montanari, C. A. (2013). Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay. PLoS Neglected Tropical Diseases, 7(8), e2370. doi:10.1371/journal.pntd.0002370
- Yuan, Y., Pei, J., & Lai, L. (2011). LigBuilder 2: A practical de novo drug design approach. Journal of Chemical Information and Modeling, 51(5), 1083–1091. doi:10.1021/ci100350u